86. 肺動脈性肺高血圧症
[臨床試験数:1,083,薬物数:667(DrugBank:122),標的遺伝子数:98,標的パスウェイ数:185

Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-003975-38-AT
(EUCTR)
03/10/201028/08/2007Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAHProof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH Pulmonary arterial hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10036727;Term: Primary pulmonary hypertension
Product Name: Terguride 0.5 mg tablet
INN or Proposed INN: Terguride
Other descriptive name: Transdihydrolisuride
Ergonex Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
99Phase 2Czech Republic;Germany;Netherlands;Austria
2EUCTR2007-003975-38-CZ
(EUCTR)
19/05/200913/02/2009Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAHProof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective Phase II proof of concept study for 12 weeks of constant treatment with Terguride or placebo - TERPAH Pulmonary arterial hypertension
MedDRA version: 9.1;Level: LLT;Classification code 10036727;Term: Primary pulmonary hypertension
Product Name: Terguride 0.5 mg tablet
INN or Proposed INN: Terguride
Other descriptive name: Transdihydrolisuride
Ergonex Pharma GmbHNULLNot RecruitingFemale: yes
Male: yes
84Phase 2Germany;Czech Republic;Netherlands;Austria